99 times the raw material: the pharmaceutical companies are afraid to cut off the supply and they can only pay the bills.

category:Global click:1687
 99 times the raw material: the pharmaceutical companies are afraid to cut off the supply and they can only pay the bills.


A few days ago, Liaoning Province Drug and medical consumables centralized purchase network issued a warning notice, involving 81 kinds of drugs that can not supply distribution normally, of which 12 drugs are not productive because of the raw material, the enterprise production line transformation and other reasons; 13 drugs are stopped from raw materials because of the purchase of raw materials; the 17 drugs are on the price of raw materials. The rise and the low price of the bid can not be supplied normally.

13 pharmaceutical companies that have stopped production of some medicines due to lack of raw materials include a Zhejiang pharmaceutical company.

In fact, Zhejiang pharmaceutical companies, which are affected by the shortage of raw materials, are not the only ones on the list.

After more than 30 years work in the pharmaceutical industry, Hu Kun, who is the head of a pharmaceutical company in Zhejiang, is seldom as irritated as he is now. He has just received a list of quotations compiled by employees. 5 kinds of raw materials are monopolized by dealers, and chlorpheniramine maleate (also known as chlorpheniramine, mainly used for rhinitis, skin mucosal allergies, and relieving tears, sneezing, runny nose, and other cold symptoms) has risen to 58 times a month, from 400 yuan /kg to 23300 yuan /kg.

Its too far out. Hu Kun said that the general distribution gave him another plan. The price of raw material drugs has doubled, but the sales of drugs give them a rebate of 0.05 yuan per tablet.

The cost of raw materials in Hun Kuns factory is increased by at least 1 million 800 thousand yuan a year based on several raw material drugs that have already increased in price. It sounds not much, but the situation is getting worse. This years raw materials exhibition, many pharmaceutical companies will not sign the contract. In his view, this is a signal, the price of raw materials should go up!

A strange strange telephone

Three years ago, almost at this time, the buyer in Hu Kun factory received a strange phone call, saying that the supply of inosine, a material for leukinia, all kinds of heart diseases and chronic hepatitis, liver cirrhosis, was linked to him. They were national sales.

At first we thought it was a fraud call, and it turned out to be a real connection with the raw material factory that was originally supplied. Hu Kun can not help but say, total distribution is only a name, in fact, is a monopoly, the national inosine raw materials production enterprises are only two or three, all supplies are pinched in their hands.

Inosine was the first thing after total distribution is the first thing is price rise: in July 2015, the price of inosine rose from 92~95 yuan /kg to 200 yuan /kg, up more than 100%; in July this year, up to 600 yuan /kg. Three years has risen 5 times.

I saw them once two years ago. Hu Kun said that the general distributors were usually contacted by telephone or WeChat with the pharmaceutical factory, and even signed the contract Dou Youdi three parties, this is a problem and can not be found on their head.

The meeting was because the other wanted to monopolize the inosine product produced in Hun Kuns factory. This level of business negotiations did not have to come up with Hu Kun, but he sneaked in by the name of the vice president of sales: I just want to know who is hiding behind the scenes.

When people came to speak Putonghua in Hubei, they said the three questions were very good. The other party asks for underwriting, and the delivery price will be 30% for me, and two years for the contract. Later, Hu Kuncai knew that this was basically the model contract of the total dealers: underwriting two to three years, and the supply price increased by 30%~50%. Few pharmaceutical factories will reject such conditions. No need to worry about sales, but two can make more money. Who will not?

One kind of API rose to 58 times a month

The market has been different from three years ago. Hu Kuns stock list of drug ingredients has changed from 2 to 5, and the trend will be more. Among them, chlorphenamine maleate, after being monopolized, surged from 400 yuan /kg to 23300 yuan /kg, up 58 times in one month.

Why dont you find another supply channel? I hope there is another way!

There are only 6 manufacturers of Chlorphenamine Maleate approved in China. But in fact, only two families are actually producing. Hu Kun confessed that the idleness of the batch is a very common situation. The market for raw materials and drugs has been fluctuating, and the price is stable. The market share of the two or three major pharmaceutical factories is basically over 90%. Therefore, it is easier to monopolize the market and manipulate prices.

Chlorphenamine maleate is a typical example. At the end of December last year, Shenyang was reported to have been reported to have illegal production of Chlorphenamine maleic acid and was recovered by the State Administration of food and drug administration, and was retracted from the GMP certificate. Since then, the nine potential pharmaceutical factory in Henan is one.

58 times the cost of API, it is estimated that the production of many pharmaceutical companies will be affected. Although chlorpheniramine is a small variety of raw materials, but the production of proprietary drugs are anti-allergic, anti-cold parity drugs, behind the market demand of nearly 100 billion yuan. Hu Kun said that the manufacturer of the finished drug processed by chlorpheniramine had a price of more than one yuan. If the cost rose so much, he could only temporarily suspend production.

Insiders said that the raw materials had gone up too fast, and the pharmaceutical companies either stopped production or increased their prices, and eventually they paid the bills.

Qianjiang Evening News reporter inquired the State Food and drug administration official website, with maleic acid chlorphenamine directly named 421 drug approval, containing maleic acid chlorphenamine components of the drug batch more than 2100, including the use of rhinitis tablets, such as a large amount of common drugs.

Small varieties and large quantities are also the two criteria for selecting distributors. Small varieties, which mean that there are not many production enterprises for this kind of API, which are easy to negotiate, and a large amount of profit is a big profit.

However, this situation has gradually deteriorated. Among the newest monopolized API varieties, glucose is in the list. Glucose is a large variety of APIs involving nearly 5,000 drug approvals, and there are countless daily doses of glucose injection alone. I didnt expect their courage to be so great that they would dare to stir up a large variety of raw materials. Hu Kun said that the latest news he heard was that even the glass bottle manufacturers who made the glucose suspended bottles had people come to the door to talk about underwriting.

Why do pharmaceutical companies dare to be angry

Not more than Hu Kun. Qianjiang Evening News reporter immediately telephoned two Zhejiang pharmaceutical companies, the other acknowledged that the price of raw materials was true, but the details of them, the suppliers involved, such as bottle.

During the two sessions of this year, Hu Jiqiang, chairman of Kant Bei, said publicly that many of the prices of raw materials have been raised twenty or thirty times more than in previous years. The price of uric acid is 30~40 yuan /kg a few years ago, and it rose to 900 yuan /kg in the last two years.

Since this is an open secret in the industry, why do most pharmaceutical companies keep silent?

An urgent problem before Hu Kun is: what should we do if we have won the bid for government procurement?

After winning the tender, abandon the tender will have to be blacklisted by the government, and then participate in the bidding will be limited, can not accept large orders, if the production according to the original order, really can not afford to lose. Hu Kun said that there had been an increase in the price of APIs after receiving orders in the past. Loss of 10%-20%, grinding teeth will be done, but now it is too much!

At lunch, Hu Kun met the sales manager and said that he had drafted a price adjustment application for government bidding products and was ready to submit it to the higher authorities the next day.

Can you be approved? Hu Kun did not know that it might be regarded as an unreasonable application and dismissed.

A few days later, Hu Kun issued a list of the latest price rises for raw materials and drugs in his circle of friends. The list has changed from 5 to 14, which were first seen by Qianjiang Evening News reporters.

The highest record was refreshed: phenol rose from 230 yuan /kg to 23000 yuan /kg, up 99 times.

Chen Chuanying, Secretary General of the provincial medical industry association:

The price of API is rising unsustainable

Just a phone call from a pharmaceutical company, Chen Chuanying had some helplessness to laugh, and to ask her to negotiate with the purchase of raw materials, as the Secretary General of the Zhejiang medical industry association, such a telephone this year she has received a lot. Scientific research (API) can also think of ways, where the volume of production is large, and where can it be coordinated? Chen Chuanying told Qianjiang Evening News that at the end of last year, the China Pharmaceutical Enterprise Management Association (CMMA) made a special investigation on the price rise of APIs.

At the end of July last year, the Zhejiang Provincial Price Bureau once forwarded the decision of the national development and Reform Commission on the misuse of the market dominance of Zhejiang Xin Zaike Pharmaceutical Co., Tianjin, Han De Wei Pharmaceutical Co., Ltd., the sale of isoniazid raw materials with unfair and high prices and the case of refusing to deal with the transaction in the case of unjustified reasons. The behaviors of the two companies were identified as price monopoly and they were fined 443 thousand and 900 yuan.

Compared with illegal income, the penalty of several hundred thousand yuan is not painful. The so-called agreement price and distribution price of APIs are no longer a secret in the industry. How much you know, but its hard to find. Chen Chuanying said, complain more than report. But the monopoly price of API is not sustainable, and the approval of the API and pharmaceutical accessories will start soon. Chen Chuanying was more optimistic. She said that last December, the management method for the approval and approval of the common review and approval of pharmaceutical materials, medicinal materials and pharmaceutical ingredients and pharmaceutical preparations began to be open to public opinion, which means that the future API will not be issued separately. That is to say the preparation enterprise can find raw material medicine for its own material, as long as the quality meets the standard, the application for related approval can be applied, and the situation of high price will be relieved. The source of this article: surging news editor: Cao Yi _NN5778

Compared with illegal income, the penalty of several hundred thousand yuan is not painful. The so-called agreement price and distribution price of APIs are no longer a secret in the industry. How much you know, but its hard to find. Chen Chuanying said, complain more than report.

But the monopoly price of API is not sustainable, and the approval of the API and pharmaceutical accessories will start soon. Chen Chuanying was more optimistic. She said that last December, the management method for the approval and approval of the common review and approval of pharmaceutical materials, medicinal materials and pharmaceutical ingredients and pharmaceutical preparations began to be open to public opinion, which means that the future API will not be issued separately. That is to say the preparation enterprise can find raw material medicine for its own material, as long as the quality meets the standard, the application for related approval can be applied, and the situation of high price will be relieved.